Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Introduction: A subgroup analysis of the CAPACITY and ASCEND trials showed that pirfenidone use beyond disease progression reduced the risk of subsequent forced vital capacity (FVC) decline and death. Our study aimed to compare the efficacy and safety of nintedanib with or without pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) who experienced disease progression during previous pirfenidone therapy. Methods: In this randomized, open-label, selection design phase II trial, patients with IPF and a ≥5% relative decline in FVC within 6 months of the pirfenidone administration period were randomly assigned to nintedanib (switch group) or nintedanib plus pirfenidone (combination group). The primary endpoint was the incidence of a ≥5% relative decline in FVC or death during the first 6 months. Results: Only 7 patients were enrolled (4 in the switch group and 3 in the combination group). Although the switch group continued with nintedanib for 1 year or more, 2 patients (66.7%) in the combination group discontinued nintedanib within 6 months due to severe adverse events. Given the slow case registration and safety concerns in the combination group, the trial was terminated without extending the registration. The incidence of a ≥5% relative decline in FVC during the first 6 months was 50.0% in the switch group and 66.7% in the combination group. There were no deaths during the observation period. Conclusions: Clinical trials verifying the use of pirfenidone after disease progression in IPF may be difficult to enroll patients. Definitive conclusions on both safety and efficacy cannot be drawn from the results of this study alone. Trial registration: UMIN Clinical Trial Registry; registration number, UMIN000019436; date of first registration, 21/10/2015; https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022471.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The INJOURNEY trial was an open-labelled, RCT of 111 IPF patients treated with nintedanib with or without pirfenidone [84]. When the combination therapy went 12 weeks, a suggestion of a further reduction in FVC decline was seen. Little change in nintedanib plasma trough levels were found.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [84]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
du Bois, R. M., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., King, T. E., Lancaster, L., Noble, P. W., Sahn, S. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201105-0840oc · Cited by 527 · cited 6×
“In case 5 of the combination group, a lung function test and SGRQ were performed for the 6-month efficacy assessment on day 167, which showed a temporary improvement in the SGRQ score and a slight increase in FVC.”
MethodInfluentialNathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., Glaspole, I., Glassberg, M. K., Kardatzke, D. R., Daigl, M., Kirchgaessler, K.-U., Lancaster, L. H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30326-5 · Cited by 335 · cited 1×
“Pirfenidone has been shown to reduce both all-cause and IPF-related mortality in a prespecified pooled analysis of CAPACITY and ASCEND trials.([5]) This pooled analysis also showed that pirfenidone use beyond disease progression reduced the risk of subsequent FVCdecline and death.”
ResultNintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial
Vancheri, C., Kreuter, M., Richeldi, L., Ryerson, C. J., Valeyre, D., Grutters, J. C., Wiebe, S., Stansen, W., Quaresma, M., Stowasser, S., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1301oc · Cited by 305
Crestani, B., Huggins, J. T., Kaye, M., Costabel, U., Glaspole, I., Ogura, T., Song, J. W., Stansen, W., Quaresma, M., Stowasser, S., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30339-4 · Cited by 247 · cited 1×
“The open-label extension of these trials (INPULSIS-ON) indicated that the nintedanib’s beneficial effect on slowing disease progression was maintainedand that thechange frombaselineFVCwasconsistent in the long term.([8]) However, the optimal treatment strategy for maximising theuseof bothpirfenidoneandnintedanibhasnot…”
BackgroundSelf-citationSafety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
Ogura, T., Taniguchi, H., Azuma, A., Inoue, Y., Kondoh, Y., Hasegawa, Y., Bando, M., Abe, S., Mochizuki, Y., Chida, K., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00198013 · Cited by 215 · cited 1×
“Although there have been two clinical trials on pirfenidone and add-on nintedanib, these trials only evaluated the short-term tolerability and safety of combination therapy and included numerous stable patients.([9,11]) In the phase IV trial, the enrolled patients showed only slight decreases in FVC and DLcowithin the…”
MethodSelf-citationNathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Glasscock, K. F., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207011 · Cited by 180 · cited 2×
“Asmentioned earlier, pirfenidoneusebeyonddisease progression can potentially reduce the risk of subsequent FVC decline and death.([6]) Several clinical trials that evaluated the safety and pharmacokinetics of the combined use of pirfenidone and nintedanib have recently been published and showed that pirfenidone combin…”
BackgroundMethod
Cited by
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)
Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17
“In a small phase 2 open-labeled trial, we evaluated ninte-danib with or without pirfenidone in IPF patients who had experienced disease progression on pirfenidone alone [84].”
Yang, K., Huang, N., Sun, J., Dai, W., Chen, M., & Zeng, J. (2022) · Peptides · doi:10.1016/j.peptides.2022.170842 · Cited by 20
Lee, J. H., & Song, J. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-946 · Cited by 15
“For intervention protocols, two studies added nintedanib to ongoing pirfenidone therapy in patients with IPF (15,17), one study added pirfenidone to nintedanib monotherapy (18), and the remaining study added another agent to preceding treatment with antifibrotic drugs (16).”
Meersseman, C., Martínez-Besteiro, E., Romain‐Scelle, N., Crestani, B., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Borie, R., Diesler, R., Valenzuela, C., et al. (2025) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2025.10.004 · Cited by 11
Gregor, J., Adir, Y., Šterclová, M., Moğulkoç, N., Kramer, M. R., Doubková, M., Plačková, M., Müller, V., Studnicka, M., Žůrková, M., et al. (2023) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2023.12.002 · Cited by 5
Metadata
- Authors
- Ikeda, S., Sekine, A., Baba, T., Kato, T., Katano, T., Tabata, E., Shintani, R., Yamakawa, H., Oda, T., Okuda, R., Kitamura, H., Iwasawa, T., Takemura, T., & Ogura, T.
- Affiliations
- Kanagawa Cardiovascular and Respiratory Center (JP)
- Japanese Red Cross Medical Center (JP)
- Corresponding author
- Ikeda, Satoshi
- ORCID
- Venue
- Medicine
- Published
- 2022-06-03
- Volume
- 101
- Issue
- 22
- Pages
- e29232
- ISSN
- 0025-7974 (ISSN-L)
- 1536-5964
- PMC
- PMC9276254
- OpenAlex
- W4281729540
- Cited by
- 11
- References
- 14
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 2 · 2023: 2 · 2022: 1
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medicine (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, nintedanib, pirfenidone, disease progression, forced vital capacity decline, combination therapy, drug switching, antifibrotic agents, adverse events, trial termination
- MeSH terms
- Humans, Indoles, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration. https://app.cochat.ai/papers/10.1097/md.0000000000029232
- The paper
- Ikeda, S., Sekine, A., Baba, T., Kato, T., Katano, T., Tabata, E., Shintani, R., Yamakawa, H., Oda, T., Okuda, R., Kitamura, H., Iwasawa, T., Takemura, T., & Ogura, T. (2022). Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration. Medicine. https://doi.org/10.1097/md.0000000000029232
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.